Return to content in this issue

 

Drug hypersensitivity in cutaneous manifestations of SARS-CoV-2 infected patients

Solano-Solares E1*, Chica-Guzmán V1*, Pérez-Allegue I1, Cabrera-Hernández R1, Fernández-Guarino M2, Fernández-Nieto D2, Moreno-García-del-Real C3, de-Andres-Martin A4, García-Bermejo L5, González-de-Olano D1,6**, de-la-Hoz-Caballer B1,6**

1Allergology Department, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
2Dermatology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
3Pathological Anatomy Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
4Immunology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
5Biomarkers and Therapeutic Targets Group, RedinRen, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
6Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Spain.
*Both authors have equally contributed and should be both considered as first authors
**Both authors should be considered as senior authors.

J Investig Allergol Clin Immunol 2022; Vol. 32(3)
doi: 10.18176/jiaci.0744

Key words: Cutaneous Manifestations, Drug Provocation T test, First Wave, SARS-CoV-2, Drug Hypersensitivity